Is combination therapy with inhaled anticholinergics and β2-adrenoceptor agonists justified for chronic obstructive pulmonary disease?

Drugs and Aging

Volumn 24, Issue 8, 2007, Pages 615-628

  Reddy, Chakravarthy B ^a   Kanner, Richard E ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FENOTEROL; FENOTEROL PLUS IPRATROPIUM BROMIDE; FORMOTEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LEVALBUTEROL; OXITROPIUM BROMIDE; PIRBUTEROL; PLACEBO; SALBUTAMOL; SALMETEROL; TERBUTALINE; TIOTROPIUM BROMIDE;

AIRWAY OBSTRUCTION; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; EVALUATION; HUMAN; HYPERINFLATION; HYPOKALEMIA; MEDICAL LITERATURE; METERED DOSE INHALER; MONOTHERAPY; NEBULIZATION; NEBULIZER; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SINGLE DRUG DOSE; TACHYCARDIA; TREMOR; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE;

EID: 34548058065     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724080-00001     Document Type: Review

References (82)

1. Global initiative for chronic Obstructive Lung Disease: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2006. Bethesda (MD): National Institutes of Health, National Heart, Lung and Blood Institute [online]. Available from URL: http://www.goldcopd.com [Accessed 2007 Mar 5]
2. Murray CJL, Lopez AD. Evidence-based health policy: lessons from the global burden of disease study. Science 1996; 274: 740-3
3. Mannino D. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002; 121 (5 Suppl.): 121S-6S
4. Murray CJL, Lopez AD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge (MA): Harvard University Press, 1996
5. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006; 27 (2): 397-412
6. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2010. Global Burden of Disease Study. Lancet 1997; 349 (9064): 1498-504
7. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000; 117 (2 Suppl.): 5S-9S
8. Anto JM, Vermeire P, Vestbo J, et al. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17 (5): 982-94
9. 1: the Lung Health Study. JAMA 1994; 272: 1497-505
10. Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-9
11. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164: S28-38
12. Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in the peripheral airways of smokers with chronic pulmonary disease. Am J Respir Crit Care Med 1998; 157: 822-6
13. 1. Am J Respir Crit Care Med 1997; 155: 852-7
14. Majo J, Ghezzo H, Cosio MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphy sema. Eur Respir J 2001; 17: 946-53
15. Hunninghake GW, Crystal RG. Cigarette smoking and lung destruction: accumulation of neutrophils in the lungs of cigarette smokers. Am Rev Respir Dis 1983; 128: 833-8
16. Tetley TD. Macrophages and pathogenesis of COPD. Chest 2002; 121: 156S-9S
17. Nelson HS. Beta-adrenergic bronchodilators. N Engl J Med 1995; 333: 499-506
18. Barnes PJ. State of the art: beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med 1995; 152: 838-60
19. Tomlinson PR, Wilson JW, Stewart AG. Inhibition by albuterol of the proliferation of human airway smooth muscle cells grown in culture. Br J Pharmacol 1994; 111: 641-7
20. Harris T, Koutsoubos V, Guida E, et al. Salmeterol modulates cell proliferation and cyclin D1 protein levels in thrombin-stimulated human cultured airway smooth muscle via an action independent of the beta2-adrenoceptor [abstract]. Am J Respir Crit Care Med 1999; 159: A530
21. Tomlinson PR, Wilson JW, Stewart AG. Salbutamol inhibits the proliferation of human airway smooth muscle cells grown in culture: relationship to elevated cAMP levels. Biochem Pharmacol 1995; 49 (12): 1809-19
22. Bloemen PG, van den Tweel MC, Henricks PA, et al. Increased cAMP levels in stimulated neutrophils inhibit their adhesion to human bronchial epithelial cells. Am J Physiol 1997; 272: L580-7
23. Bolton PB, Lefevre P, McDonald DM. Salmeterol reduces early- and late-phase plasma leakage and leukocyte adhesion in rat airways. Am J Respir Crit Care Med 1997; 155: 1428-35
24. Bowden JJ, Sulakvelidze I, McDonald DM. Inhibition of neutrophil and eosinophil adhesion to venules of rat trachea by beta2-adrenergic agonist, formoterol. J Appl Physiol 1994; 77: 397-405
25. Ottonello L, Morone P, Dapino P, et al. Inhibitory effect of salmeterol on the respiratory burst of adherent human neutro-phils. Clin Exp Immunol 1996; 106: 97-102
26. Dowling RB, Rayner CF, Rutman A, et al. Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa. Am J Respir Crit Care Med 1997; 155: 327-36
27. Dowling RB, Johnson M, Cole PJ, et al. Effect of salmeterol on Haemophilus influenzae infection on respiratory mucosa in vitro. Eur Respir J 1998; 11: 86-90
28. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115 (4): 957-65
29. Cockcroft DW, Swystun VA. Functional antagonism: tolerance produced by inhaled beta-2 agonists. Thorax 1996; 51: 1051-6
30. 2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162: 75-80
31. Wechsler ME, Lehman E, Lazarus SC, et al. β-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173: 519-26
32. Rennard SI, Serby CW, Ghafouri M, et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD: a retrospective analysis of data from seven clinical trials. Chest 1996; 110 (1): 62-70
33. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: anticholinergics, but not β-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 2006; 21: 1011-9
34. Ikeda A, Nishimura K, Koyama H, et al. Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 48-53
35. Bellamy D, Hutchison DCS. The effects of salbutamol aerosol on lung function in patients with pulmonary emphysema. Br J Dis Chest 1981; 75: 190-6
36. Guyatt GH, Townsend M, Pugsley SO, et al. Bronchodilators in chronic air-flow limitation: effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis 1987; 135: 1069-74
37. Man WD, Mustfa N, Nikoletou D, et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax 2004; 59 (6): 471-6
38. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23 (6): 832-40
39. Martin RJ, Bartelson BL, Smith P, et al. Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD. Chest 1999; 115 (5): 1338-45
40. Barnes PJ, Basbaum CB, Nadel JA. Autoradiographic localization of autonomic receptors in airway smooth muscle: marked differences between large and small airways. Am Rev Respir Dis 1983; 127: 758-62
41. O'Donnell DE, Lam MIU, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 542-9
42. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise tolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 770-7
43. American Thoracic Society statement: standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152 Suppl. 5: 77-121
44. British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease: the COPD Guidelines Group of the Standards Care Committee of the BTS. Thorax 1997; 52 Suppl. 5: 1-28
45. Toews ML, Bylund DB. Pharmacologic principles for combination therapy. Proc Am Thorac Soc 2005; 2: 282-9
46. Easton PA, Jadue C, Dhingra S, et al. A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. N Engl J Med 1986; 315: 735-9
47. Serra C, Giacopelli A, Luciani G. Acute controlled study of the dose-response relationship of fenoterol, ipratropium bromide and their combination. Respiration 1986; 50: 144-7
48. Huhti E, Poukkula A. Comparison of fenoterol, ipratropium bromide, and their combination in patients with asthma or chronic airflow obstruction. Respiration 1986; 50: 298-301
49. Ikeda A, Nishimura K, Koyama H, et al. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: comparison with ipratropium bromide alone. Chest 1995; 107: 401-5
50. Tang OT, Flatley M. A comparison of effects of inhaling a combined preparation of fenoterol with ipratropium bromide (Duovent) with those of fenoterol and salbutamol. Postgrad Med J 1984; 60: 24-7
51. Hughes JA, Tobin MJ, Bellamy D, et al. Effects of ipratropium bromide and fenoterol aerosols in pulmonary emphysema. Thorax 1982; 37: 667-70
52. Imhof E, Elsasser S, Karrer W, et al. Comparison of bronchodilator effects of fenoterol/ipratropium bromide and salbutamol in patients with chronic obstructive lung disease. Respiration 1993; 60: 84-8
53. Tobin MJ, Hughes JA, Hutchison DCS. Effects of ipratropium bromide and fenoterol aerosols on exercise tolerance. Eur J Respir Dis 1984; 65: 441-6
54. Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch Intern Med 1999; 159: 156-60
55. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest 1994; 105 (5): 1411-9
56. Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic evaluation of a combination ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115 (3): 635-41
57. Benayoun S, Ernst P, Suissa S. The impact of combined inhaled bronchodilator therapy in the treatment of COPD. Chest 2001; 119: 85-92
58. O'Driscoll BRC, Kay BEA, Taylor RJ, et al. A long-term prospective assessment of home nebulizer treatment. Respir Med 1992; 86: 33-8
59. COMBIVENT inhalation solution study group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997; 112 (6): 1514-21
60. Gross N, Tashkin D, Miller R, et al. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in treatment of chronic obstructive pulmonary disease. Respiration 1998; 65: 354-62
61. Levin CD, Little KS, Laughlin KR, et al. Addition of anticholinergic solution prolongs bronchodilator effect of beta-2 agonists in patients with chronic obstructive pulmonary disease. Am J Med 1996; 100 Suppl. 1A: 40S-8S
62. Tashkin DP, Bleecker E, Braun S, et al. Results of a multicenter study of nebulized inhalant bronchodilator solutions. Am J Med 1996; 100: 62S-9S
63. Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778-84
64. Wadbo M, Lofdahl CG, Larsson K, et al. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J 2002; 20: 1138-46
65. Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled beta-2 adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 163 (5): 1087-92
66. Konermann M, Suchantke R, Mogck J, et al. Formoterol monotherapy compared with combination of ipratropium bromide plus fenoterol in the treatment of chronic obstructive pulmonary disease. Clin Drug Invest 2001; 21 (4): 235-42
67. Matera MG, Caputi M, Cazzola M. A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. Respir Med 1996; 90: 497-9
68. Sichletidis L, Kottakis J, Marcou S, et al. Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD. Int J Clin Pract 1999; 53: 185-8
69. Cazzola M, Di Perna F, Centanni S, et al. Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease. Thorax 1999; 54: 1083-6
70. Cazzola M, Matera MG, Di Perna F, et al. Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD. Respir Med 1999; 93: 909-11
71. van Noord JA, de Munck DRAJ, Bantje ThA, et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15: 878-85
72. D'Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium. Chest 2001; 119: 1347-56
73. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium and salmeterol. Chest 2002; 122: 47-55
74. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared to twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404
75. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-24
76. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19: 209-16
77. Cazzola M, Centanni S, Santus P, et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 2004; 98: 1214-21
78. Cazzola M, Di Marco F, Santus P, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004; 17: 35-9
79. van Noord JA, Aumann J, Janssens E, et al. Tiotropium mainte nance therapy in patients with COPD and the 24-h spirometric benefit of adding once or twice daily formoterol during 2-week treatment periods [abstract]. Am J Respir Crit Care Med 2003; 167 (S7): A95
80. van Noord JA, Aumann J, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214-22
81. van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129: 509-17
82. Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting β-agonists on severe asthma exacerba tions and asthma-related deaths. Ann Intern Med 2006; 144: 904-12